2011 - issue 1

Table of ContentsMessage from the Director 1

Coordinator also a Recipient 2

New Faculty 3-4

Presentations & Publications 5-9

2011 Walk to Cure Diabetes 10

Division Update 11

Center Expands, Renamed BCM Liver, Kidney and Pancreas Center

A Message from the Director

2011 marks the expansion of our clinical services. The center will now offer pancreas and expanded renal transplant service, creating a multidiscipline BCM Liver, Kidney and Pancreas Center. New team members of specialized transplant nephrologists, renal and pancreas transplant surgeons, and transplant coordinators have joined our group in recent months. Ronald H. Kerman, PhD is setting up an immune evaluation laboratory to give us the advantage of an on site tissue typing lab that will work directly with the transplant team to ensure the patients are matched with the best possible allografts, giving them improved outcomes both short and long-term.

Jacqueline Lappin, MD, will act as Surgical Director of the Pancreas Transplant Program. Lappin ran the largest pancreas transplant service in South Texas. Charles T. Van Buren, MD will bring his vast transplant experience to the group, and will remain Surgical Director of Renal Transplant at St. Luke's Episcopal Hospital. Van Buren performed the very first liver transplant in Houston in 1985.

The entire team, including more than two dozen lab technicians, nurse coordinators and administrative staff were recently recruited from Memorial Hermann and UTHealth's transplant program, transferring the entire program to Baylor College of Medicine and it's affiliates.

Last year, the Division performed our 1,000th successful liver transplant, while maintaining the highest liver transplant survival rate in the nation, with a one-year adult patient survival rate of 96.5 percent, compared to the national expected survival rate of 89.38 percent.

John A. Goss, MDDr. Goss is Professor of Surgery and Chief of the Division of Abdominal Transplantation and Hepatobiliary Surgery in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine in Houston.

The Michael E. DeBakey Department of Surgery

2

St. Luke's Shannon Cook has unique perspective on her job

Transplant Coordinator also an Organ Recipient

When Shannon Cook, RN comes to work at St. Luke’s Cooley Transplant Center, she doesn’t just come as a highly experienced Senior Liver Transplant Coordinator; she comes as a transplant recipient.

At the age of fourteen, Shannon Cook was diagnosed with kidney disease, cause undetermined. By age sixteen, Cook was confined to a dialysis machine ending her “normal” teenage life. She went from high school to home school spending three days a week in four hour sessions of hemodialysis which left her with no energy to enjoy the little free time she had. Due to her illness and the effects of dialysis, Cook missed much of her schooling and had to make up classes every summer.

When Shannon Cook turned 18, she was told by a fellow dialysis patient that kidney transplant could be an option. Determined not to be on dialysis for life, young Cook immediately did her own research. Her sister, who was nineteen at the time offered to donate one of her kidneys if compatible. Shannon Cook’s parents were adamant about transplantation; transplant was not much talked about twenty years ago and they feared they would be “rocking the boat” being that Cook was doing relatively well on dialysis.

But for Cook, dialysis was not a life; it was confinement, lack of freedom, pain, and exhaustion. She knew that if her sister was not a match she would stop dialysis and let life take its toll. Fortunately, her sister was a match and the transplant was performed when Cook was 19 years old. This past August, Shannon celebrated 20 years of success with her sister’s kidney.

Even before her transplant, Shannon Cook knew she wanted to be a nurse and work in the field of transplantation. “It was always around me; it just was part of my life.” After transplant, Cook graduated from high school and attended college

becoming a nurse. She worked as a hospital floor nurse, then moved to ICU, and finally to transplant in 1999. Today, she works with liver transplant patients at St. Luke’s and serves as an inspiration to them and their families.

As a transplant recipient Cook says she encourages her patients to work harder on their recovery, and to be diligent with their medications and exercise programs. “Patients often tell me that I don’t know how they feel and that I don’t understand what they are going through. I pause and say, ACTUALLY…I do, let me tell you my story…” During transplant education classes, Cook will occasionally mention her experience as a transplant recipient. When she does, people sit quietly, look at one another, and look back up at Cook with surprise and sometimes shock. “I think they are shocked to see someone so healthy, young, and working. It’s as if I’m suddenly one of their own, not just their nurse. I’m happy to be a shoulder to cry on but I always balance it with my role as a nurse who expects them to be good compliant patients.”

Today, twenty years post-kidney transplant, Shannon Cook, RN lives life to the fullest. She has a vibrant career helping liver transplant patients with their recovery, her home life is fulfilled with a wonderful husband and eight year old son, and she has the freedom to travel, wake board, and do what she loves to do. “I love my job because I know that transplant works! I couldn’t do what I do if I didn’t believe in it.”

By Sofia Perches, J.D.Outreach CoordinatorSt. Luke's Cooley Transplant Center

To find out more about transplantation at St. Luke's visit: www.stlukeshouston.com/transplant

Reprinted with permission - St. Luke's Episcopal Hospital

Even before her transplant, Shannon Cook knew she wanted to be a nurse and work in the field of transplantation.

Shannon Cook, RN

Senior Liver Transplant Coordinator,St. Luke's Cooley Transplant Center

Transplant SurgeryNew Faculty

Jacqueline Lappin, MD Associate Professor Surgical Director, Pancreas Transplant Program - St. Luke's Episcopal Hospital

Charles T Van Buren, MDProfessor Surgical Director, Kidney Transplant Program - St. Luke's Episcopal Hospital

Kanae Ishihara, MDAssociate Professor Transplant Nephrology

BVR Murthy, MD, DMProfessor Medical Director, Pancreas Transplant Program - St. Luke's Episcopal Hospital

Stephen M. Katz, MDAssociate Professor Renal Transplant

Transplant Nephrology

Barbi Witz, PA-CInstructor in Surgery Physician Assistant

3

4

Immune Evaluation LaboratoryNew Faculty

Ronald H. Kerman, PhDProfessor Director, Immune Evaluation Laboratory

Jerome Saltarrelli, PhD Instructor in Surgery Director-in-Training, Immune Evaluation Laboratory

Daniel J. Cook, PhD Clinical Professor Co-director, Immune Evaluation Laboratory

Lazslo Bihari, MDAssistant Professor

The BCM Immune Evaluation Laboratory provides Human Leukocyte Antigen (HLA) typing, antibody screening and crossmatching services for many of the transplant centers throughout the Texas Medical Center. These tests are required for patients being evaluated for organ transplantation.

PresentationsJohn A. Goss, MD

“Biliary Complications,” 2011 Studies of Pediatric Liver Transplantation (SPLIT), Atlanta, GA, September 22-23, 2011.

“Surgical Aspects of Management of HCC,” St. Luke’s Episcopal Hospital Hot Topics Conference, Houston, TX, October 15, 2011.

“Advances in Surgery and Transplantation,” 2nd Annual AASLD Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, December 3, 2011.

Risë Stribling, MD

“Management of Hepatocellular Carcinoma,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Pregnancy and Liver Disease,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, June 27, 2011.

“!e Road to Transplantation: Options for Patients with Organ Failure,” CME Presentation at Kingwood Medical Center, Kingwood, TX, August 11, 2011.

F. Blaine Hollinger, MD

“HBV: When to Start Treatment and When to Stop?,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Clinical Signi"cance of Occult Hepatitis B in Blood Donors,” 21st Conference of APASL, February 17-20, 2011.

“Occult HBV/HCV Relevance in Clinical Hepatology,” Dr. SR Naik Memorial Oration, 19th Meeting of the Indian National Association for Study of the Liver, Chandigarh, India, March 25-27, 2011.

“Occult HBV and Reactivation,” 2nd Annual AASLD Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, December 3, 2011.

“Occult Hepatitis B Virus,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, December 12, 2011.

Ronald H. Kerman, PhD

“Transplant Antibodies: Which Ones Are Clinically Relevant? (If antibody is detected, Should it be respected?),” Semmelweis Symposium 2011, Budapest, Hungary, November 5, 2011.

Khozema Hussain, MD

“Management of Hepatocellular Carcinoma,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Management of Hepatocellular Cancer,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, March 28, 2011.

“Acute Liver Failure and Arti"cial Liver Support,” 2nd Annual AASLD Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, December 3, 2011.

Jacqueline Lappin, MD

“Solid Organ Pancreas Transplantation: A Review,” In-Service Lecture, St. Luke’s Episcopal Hospital, July 21, August 4, 5, 15, 20, 25, September 6, 8 and 9, 2011.

“Solid Organ Pancreas Transplantation: A Review,” Surgery Grand Rounds, !e Michael E. DeBakey Department of Surgery, Baylor College of Medicine, October 5, 2011.

Norman L. Sussman, MD

“2011 Simply Speaking™ HBV An Expert Educator's CME Lecture Series,” New Orleans, LA, January 14-15, 2011.

“Fatty Liver: Weighing the Evidence,” Medicine Grand Rounds, St. Luke’s Episcopal Hospital, Houston, TX, January 24, 2011.

“Acute Liver Failure,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, February 7, 2011.

5

“Managing Acute Liver Failure,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Emerging Antiviral Treatments and Management Approaches for Chronic HCV Infection,” Clinical View Points, A CME Lecture Series for HCV, Twin Falls, Idaho. February 26, 2011.

“Unusual Case of Acute Liver Failure,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, February 28, 2011.

“Alcoholic Liver Disease,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, March 14, 2011.

“Pentoxyfyline,” “Management of End-Stage Liver Disease and Alcoholic Liver Disease,” and “Lactulose,” Scripps Clinic’s 26th Annual New Treatments in Chronic Liver Disease Conference, San Diego, CA, March 26-27, 2011.

“Fatty Liver Disease—the metabolic consequences of carbohydrate and fructose in the American Diet,” GI Grand Rounds, Scott and White Hospital, Temple, TX, April 7, 2011.

“Emerging Antiviral Treatments and Management Approaches for Chronic HCV Infection,” Clinical View Points, A CME Lecture Series for HCV, Salt Lake City, UT, April 28, 2011.

“Discuss Application of Arti"cial Liver in Clinical Medicine,” Fifth Annual Clinical Research Symposium, St. Luke’s Episcopal Hospital, Houston, TX, May 18, 2011.

“National Hep B and C Training Program and Treatment Update 2011,” Scripps Clinic Liver Research Consortium, Houston, TX, August 13, 2011.

“Emerging Antiviral Treatments and Management Approaches for Chronic HCV Infection,” Clinical View Points, A CME Lecture Series for HCV, Grapevine, TX, September 13, 2011.

“Case Discussions (Putting it into Practice),” Plenary Session: “Fatty Liver—Up and Coming Disease,” 12th Annual International Hot Topics in Liver Disease Conference

“Alcoholic Liver Disease and Management of Decompensated Cirrhosis,” Scripps 26th Annual Liver Update, La Jolla, CA, 2011.

Gagan K. Sood, MD

“Managing Portal Hypertension—An Update,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Genetics of Hepatic Steatosis,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, May 2, 2011.

“Portal Hypertension,” 1st Annual DDW Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, June 10-11, 2011.

“Hepatorenal Syndrome,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, October 3, 2011.

“Advances in the Management of Varices,” 2nd Annual AASLD Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, December 3, 2011.

John M. Vierling, MD

“HCV: How are you Going to Use New Drugs?,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“HCV Lifecycle and Resistance to Direct-Aging Antiviral Agents,” European HCV Speakers' Forum; JMV Co-Chairman, Amsterdam, March 3, 2011.

“HCV Lifecycle and Resistance to Direct-Aging Antiviral Agents,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, March 7, 2011.

“Diagnosis and Management of AIH” and “Primary Biliary Cirrhosis: Update 2011,” University of Miami, Eugene B. Schi# Liver Center Conference, Miami, FL, March 25-26, 2011.

European Association for the Study of the Liver, Berlin, Germany, March 30 to April 3, 2011

Poster Presentations:“Utility of Historical Data Compared to Lead-In Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated with Boceprevir+Peninterferon Alfa-2B/Ribavirin (P/R)”

6

“Unique Pattern of Virologic Response in Patients with Genotype-1 HCV: A Phase II Study of CTS-1027 in Combination with Peginterferon/Ribavirin (SOC) in Null Responders”

“Pegylated Interferon-Lambda (PEGIFN-O) Shows Superior Viral Response with Improved Safety and Tolerability Versus PEGIFND-2A in HCV Patients (G1/2/3/4): Emerge Phase IIB !rough Week 12”

“High Sustained Virologic Response (SVR) Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-treated with Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin”

“Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus (HCV) Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of Sprint-2 and Respond-2 Studies”

“Overall Safety Pro"le of Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“E$cacy Among North American and European HCV Genotype-1 Treatment-Naïve and Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Treated with Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“Four-Week !erapy with Peginterferon Alfa-2B/Ribavirin E#ectively Predicts Sustained Virologic Response in Treatment-Naïve and Previous-Treatment-Failure Patients with HCV-1 Treated with Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated with Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“First SVR Data with the Nucleoside Analogue Polymerase Inhibitor Mericitabine (RG7128) Combined with Peginterferon/Ribavirin in Treatment-Naïve HCV G1/4 Patients: Interim Analysis From the Jump-C Trial”

“Immunology of Hepatitis B Virus Infection,” 2011 Shanghai International Integrative Medicine Congress, Shanghai International Convention Center, Shanghai, China, April 21-26, 2011.

“Update on Autoimmune Liver Disease,” Chair, AASLD State-of-the-Art Lecture; “Best of DDW 2011”, Co-Chair, DDW Plenary Session, Digestive Disease Week (DDW), Chicago, IL, May 7-10, 2011.

Oral presentations:“Four-Week !erapy With Peginterferon Alfa-2B/Ribavirin E#ectively Predicts Sustained Virologic Response in Treatment-Naïve and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin”

“Novel !erapies for HCV Infection,” 5th Annual Clinical Research Symposium, Houston, TX, May 18, 2011.

“HCV !erapeutic Update,” !e University of Texas Medical Branch GI Conference, Galveston, TX, May 24, 2011.

“Novel !erapies for HCV Infection,” 1st Annual DDW Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX June 10-11, 2011.

“HCV Protease Inhibitors: Mining Phase 3 Study Results for Personalized Care,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, June 20, 2011.

“!erapy for HCV Infections,” Baylor College of Medicine, Department of Medicine Grand Rounds, Houston, TX, July 28, 2011.

“Combination and New !erapies in Development for Chronic Hepatitis C,” “Management of Side E#ects of HCV !erapy” and “Management of Antiviral Resistance in HCV !erapy,” Scripps Annual Update, Houston, TX, August 13, 2011.

“Clinical Advances in the Management of Cirrhotics,” Chronic Liver Disease Foundation, Houston, TX, September 15, 2011.

“Novel !erapies for Chronic Hepatitis C,” Excellence Award Lecture GCSGI, Houston, TX, September 29, 2011.

“Autoimmune Hepatitis,” St. Luke’s Episcopal Hospital Hot Topics Conference, Houston, TX, October 15, 2011.

7

8

62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, November 4-8, 2011.

“HIV Infection and the Liver,” “Autoimmunity and DILI” and “Wrap-up Comments,” and “Rifaximin Treatment in Hepatic Encephalopathy, NEJM”

Parallel Session Presentations:“IL28B C/C Genotype is Predictive of %1 Log10 IU/mL Reduction in Plasma HCV RNA after 4 Weeks of Peginterferon (PEGIFN) and Ribavirin (RBV) !erapy: Implications for the use of the Lead-In Strategy for Direct-Acting Antiviral-Based Treatment Regimens”

“E$cacy, Safety, And Metabolic E#ects in Chronic Hepatitis C (CHC) Genotype 1 (G1) Patients with Insulin Resistance (IR) Treated with Pioglitazome (PIO) and Peginterferon Alfa-2A Plus Ribavirin (P/R)”

“Analysis of Resistance-Associated Amino Acid Variants (RAVS) in Non-SVR Patients Enrolled in a Retrospective Long-Term Follow-up Analysis of Boceprevir Phase 3 Clinical Studies”

“Reactivation of Hepatitis B Infection Among Patients with Cancer”

Plenary Session Presentation:“BMS-790052, A NS5A Replication Complex Inhibitor, Combined with Peginterferon Alfa-2A and Ribivirin in Treatment-Naïve HCV-Genotype 1 or 4 Patients: Phase 2B AI444010 Study Interim Week 12 Results”

Poster Sessions:“E$cacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavirin: !e Provide Study”

“Concomitant Medication Use in Patients with Hepatitis C Genotype 1 Treated with Boceprevir (BOC) Combination !erapy”

“Overall Safety Pro"le of Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin in Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin”

“Reasons for Screen Failure in 2 Phase III Studies of Boceprevir with Peginterferon/Ribavirin in Patients with Chronic HCV Genotype 1 Infection (Sprint-2 and Respond-2)”

“Safety and E$cacy of Pegylated Interferon Lambda (PEG-LAMBDA) Compared to Pegylated Interferon D-2A (PEG-ALFA) in HCV-Infected Patients (G1/2/3) with Compensated Cirrhosis: Emerge Phase IIB E$cacy and

Safety Results !rough Week 12”

“Once Daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in Combination with Peginterferon Alfa-2B/Ribavirin (PR) for 12 Weeks Plus 12 weeks PR in Treatment-Naïve Patients with HCV Genotype 1 (G1): SVR Results from Next-1, A Phase 2 Study”

“Biochemical and Immunologic E#ects of Rituximab in Primary Biliary Cirrhosis with an Incomplete Response to Ursodeoxycholic Acid”

“Novel !erapies for Chronic Hepatitis C,” GI Section Lecture, Baylor College of Medicine, Houston, TX, December 1, 2011.

“Other Novel !erapies for HCV Infections,” 2nd Annual AASLD Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, December 3, 2011.

“HCV !erapy,” VA Medicine Grand Rounds, Michael E. DeBakey VA Medical Center, Houston, TX, December 19, 2011.

Prasun Jalal, MD

“Non-invasive Markers of Liver Fibrosis,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, January 10, 2011.

“Non-invasive Liver Tests: Do We Still Need a Liver Biopsy?,” Baylor College of Medicine GI and Liver Course 2011, Department of Medicine, Section of Gastroenterology and Hepatology, Houston, TX, February 11-12, 2011.

“Management of Autoimmune Hepatitis with Acute Liver Failure,” Dr. SR Naik Memorial Oration, 19th Meeting of the Indian National Association for Study of the Liver, Chandigarh, India, March 25-27, 2011.

“Management of Autoimmune Hepatitis-Induced Acute Liver Failure,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, April 4, 2011.

“Management of Hepatitis C,” St. Luke’s Episcopal Hospital Medicine Grand Rounds, Houston, TX, April 11, 2011.

“Hepatitis C and Kidney Disease,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, April 18, 2011.

9

“Steatohepatitis,” 1st Annual DDW Highlights Conference, Texas Gulf Coast Gastroenterological Society, Houston, TX, June 10-11, 2011.

“HBV Guidelines Review,” Simply Speaking HBV meeting, Houston, TX, August 25, 2011

“Hemochromatosis,” Hepatology/Liver Transplantation Conference, Baylor College of Medicine, Houston, TX, September 12, 2011.

“Clinical Advances in the Management of Cirrhotics,” Chronic Liver Disease Foundation, Houston, TX, October 26, 2011.

PublicationsDasgupta A, Moreno V, Balark S, Smith A, Sonilal M, Tejpal N, Van Buren CT. Rapid Estimation of Whole Blood Everolimus Concentrations Using Architect Sirolimus Immunoassay and Mathematical Equations: Comparison with Everolimus Values Determined by Liquid Chromatography/Mass Spectrometry. J Clin Lab Anal; 25(3):207-11, 2011. ABSTRACT

Brunicardi FC, Gibbs RA, Wheeler DA, Nemunaitis J, Fisher W, Goss J, Chen C. Overview of the Development of Personalized Genomic Medicine and Surgery. World J Surg; 35(8):1693-9, 2011. ABSTRACT

Harring TR, Guiteau JJ, Nguyen NT, Cotton RT, Gingras MC, Wheeler DA, O'Mahony CA, Gibbs RA, Brunicardi FC, Goss JA. Building a Comprehensive Genomic Program for Hepatocellular Carcinoma. World J Surg; 35(8):1746-50, 2011. ABSTRACT

Nguyen NT, Vierling JM. Acute Liver Failure. Curr Opin Organ Transplant; 16(3):289-96, 2011. ABSTRACT

Vierling JM, Hreha G, Wang H, Braun M. !e role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease. Trans Am Clin Climatol Assoc. 2011;122:326-35. ABSTRACT

Sussman NL, Kochar R, Fallon MB. Pulmonary complications in cirrhosis. Curr Opin Organ Transplant; 16(3):281-8, 2011. ABSTRACT

Nguyen NT, Cotton RT, Harring TR, Guiteau JJ, Gingras MC, Wheeler DA, O'Mahony CA, Gibbs RA,

Brunicardi FC, Goss JA. A Primer on a Hepatocellular Carcinoma Bioresource Bank Using the Cancer Genome Atlas Guidelines: Practical Issues and Pitfalls. World J Surg; 35(8):1732-7, 2011. ABSTRACT

Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011 Aug;15(3):515-36. ABSTRACT

Desai MS, Zainuer S, Kennedy C, Kearney D, Goss J, Karpen SJ. Cardiac Structural and Functional Alterations in Infants and Children with Biliary Atresia, Listed for Liver Transplantation. Gastroenterology. 2011 Oct;141(4):1264-1272. ABSTRACT

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1207-17. ABSTRACT

Vierling JM. Autoimmune hepatitis and antigen-speci"c T regulatory cells: when can we send in the regulators? Hepatology. 2011 Feb;53(2):385-8. ABSTRACT

Merwat SN, Vierling JM. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis. 2011 Feb;15(1):131-52. Review. ABSTRACT

Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Treatment of Liver Metastases in Patients With Neuroendocrine Tumors: A Comprehensive Review. Int J Hepatol. 2011;2011:154541. ABSTRACT

Harring TR, O'Mahony CA, Goss JA. Extended Donors in Liver Transplantation. Clin Liver Dis. 2011 Nov;15(4):879-900. ABSTRACT

OUTTAKES

10

Clinics and Centers

2011 Walk to Cure Diabetes

St. Luke's Cooley Transplant Center6720 Bertner AvenueHouston, TX 77030Toll-Free: (877) 685-0361 International Patients: (832) 355-3350

St. Luke's Center for Liver Disease

6620 Main, Suite 1475Houston, Texas 77030Tel: (713) 798-8355Appointments: (713) 798-6243

Texas Children's Transplant Services11th floor, Clinical Care Center6621 Fannin StreetHouston, Texas 77030Tel: (866) 683-8032For referral or other information: (832) 822-1551

Michael E. DeBakey VA Medical Center

2002 Holcombe BoulevardHouston, Texas 77030Tel: (713) 794-8985Toll-Free: (800) 639-5137, Option 1

Transplant Team represents BCM and SLEHThe Juvenile Diabetes Research Foundation (JRDF)

2011 Walk to Cure Diabetes was held Saturday, October 29th at Reliant Park. Faculty, staff and their families from the Abdominal Transplant Center at Baylor College of Medicine and the St. Luke's Cooley Transplant Center made up the 28 member team. The team, along with 15,000 other walkers, were on hand to raise money for Type-1 Diabetes research.

Over 25 million people in the US have diabetes. Complications include: Heart disease, stroke, high blood pressure, blindness, kidney disease (diabetes is the leading cause of kidney failure), and nervous system diseases.

Source: 2011 National Diabetes Fact Sheet - CDC Team members were easy to spot in their shirts featuring this 3D graphic designed by Scott Holmes.

The Abdominal Transplant Newsletter is a publication of The Michael E. DeBakey Department of Surgery at Baylor College of Medicine (For best results, use Adobe Acrobat Viewer)

To be added to the Newsletter e-mail database please write to:

Scott HolmesOne Baylor Plaza, MS: BCM 504Houston, Texas 77030or e-mail: scotth@bcm.edu

Editor-in-Chief John Goss, MDEditor Scott C. Holmes

2011 - issue 1

Division Update

Charles T. Van Buren, MDProfessor

Ronald H. Kerman, PhDProfessor

Jacqueline Lappin, MDAssociate Professor

Stephen M. Katz, MDAssociate Professor

Bhamidipati Murthy, MDProfessor

Kanae Ishihara, MDAssociate Professor

Daniel J. Cook, PhD Clinical Professor of Surgery

Laszlo Bihari, MDAssistant Professor

Jerome Saltarrelli, PhDInstructor in Surgery

Barbi Witz, PA-CInstructor in Surgery

James E. Hyland IIIAdministrative Associate

Scott C. HolmesMedical Illustration Supervisor

Barbara ShakExecutive Secretary

New Faculty and Staff

Honors and Awards

Barbi Witz, PA-C, an instructor with the Division, was elected President of the Texas Gulf Coast Physician Assistant Association for 2011-2013.

Jerome Saltarrelli, PhD, was elected to a 3-year term as Histocompatibility Councilor for the Texas Transplantation Society, July 2011.

Scott Holmes, was named the webmaster of the Texas Transplantation Society, October 2011.

Eva McKissickSenior Histocompatibility Technologist

Noriel AcordaSenior Histocompatibility Technologist

Craig AdkinsHistocompatibility Technologist I

Alfred John Eaton, IVHistocompatibility Technologist I

Phillip EriceHistocompatibility Technologist I

Jenna MitchellHistocompatibility Technologist I

Nicholas WoolleyHistocompatibility Technologist I

Clair HollingsworthHistocompatibility Technologist I

Luis RodriguezHistocompatibility Technologist I

Catherine Carter, RNSenior Research Nurse

Cathy AcevedoMedical Assistant II

Dan Yang Liu, MDSenior Research Assistant

LaSaundra Garrett Senior Support Specialist

11© 2011 Baylor College of Medicine